Type A foot-and-mouth disease genetic engineering multi-epitope protein and vaccine

Abstract

The invention provides a type A foot-and-mouth disease genetic engineering multi-epitope protein, which is characterized in that the amino acid sequence of the multi-epitope protein is SEQ ID No.2 in the sequence table. The invention also provides a vaccine containing the type A foot-and-mouth disease genetic engineering multi-epitope protein. By immunizing animals with the vaccine provided by the invention, after one week, a type A foot-and-mouth disease virus specific antibody can be detected, the antibody titer increases continuously, and the antibody titer can be the highest after four weeks of immunization. After counteracting toxicity with type A foot-and-mouth disease prevalent virus, vaccine immunized group pigs can all resist virulent attack completely. Thus, the vaccine provided by the invention can be used as a novel type A foot-and-mouth disease genetic engineering vaccine.

Description

technical field [0001] The invention belongs to the technical field of foot-and-mouth disease immunity, and in particular relates to a type A foot-and-mouth disease genetic engineering complex epitope protein and a vaccine. Background technique [0002] Foot-and-mouth disease (FMD) is an acute, highly contagious, febrile infectious disease of cloven-hoofed animals caused by foot-and-mouth disease virus (FMDV), known for its rapid spread and high infection rate. Once the disease breaks out, it will cause huge economic losses. There are seven serotypes of FMDV, namely O, A, C, Asia1, SAT1, SAT2, and SAT3. [0003] Foot-and-mouth disease has been prevalent in my country for a long time, and the currently prevalent serotypes mainly include type O and type A. The Asia1 type is basically under control (Since May 2009, the Asia I type has not occurred in my country in the past 6 years). The prevalence of type O has eased, the prevalence of type A has increased, and the number of...

AI Technical Summary

Problems solved by technology

However, due to the weak immunogenicity of FMD virus itself and the limitation of the production cost of inactivated vaccines, the duration of immunity of the vaccine is short, the level of protection is low, and the individual differences are large, and the level of protective antibody production is not uniform; At the same time, the production of inactivated vaccines requires high-level protective measures to eliminate potential safety hazards such as virus escape; moreover, multiple immunizations of non-purified inactivated vaccines will produce non-structural protein antibodies, which brings difficulties to the differential diagnosis of infected animals and immunized animals

In addition, vaccination with whole-virus inactivated vaccines cannot block the persistent infection state of the virus

Images